Overview

  • Product name
    Anti-Tau antibody [E178]
    See all Tau primary antibodies
  • Description
    Rabbit monoclonal [E178] to Tau
  • Host species
    Rabbit
  • Tested applications
    Suitable for: IHC-P, WB, IPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Mouse, Rat, Human
    Predicted to work with: Cow
  • Immunogen

    Synthetic peptide within Human Tau aa 700 to the C-terminus. The exact sequence is proprietary.
    Database link: P10636

  • Positive control
    • WB: SH-SY5Y cell lysate. IHC-P: Human brain.
  • General notes

    A trial size is available to purchase for this antibody.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab32057 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/500 - 1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
WB 1/5000. Predicted molecular weight: 79 kDa.
IP 1/100.
  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function
      Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
    • Tissue specificity
      Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
    • Involvement in disease
      Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
      Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
      Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
      Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
      Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
    • Sequence similarities
      Contains 4 Tau/MAP repeats.
    • Developmental stage
      Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
    • Domain
      The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
    • Post-translational
      modifications
      Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
      Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
      Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
    • Cellular localization
      Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
    • Information by UniProt
    • Database links
    • Form
      There are 9 isoforms produced by alternative splicing.
    • Alternative names
      • AI413597 antibody
      • AW045860 antibody
      • DDPAC antibody
      • FLJ31424 antibody
      • FTDP 17 antibody
      • G protein beta1/gamma2 subunit interacting factor 1 antibody
      • MAPT antibody
      • MAPTL antibody
      • MGC134287 antibody
      • MGC138549 antibody
      • MGC156663 antibody
      • Microtubule associated protein tau antibody
      • Microtubule associated protein tau isoform 4 antibody
      • Microtubule-associated protein tau antibody
      • MSTD antibody
      • Mtapt antibody
      • MTBT1 antibody
      • MTBT2 antibody
      • Neurofibrillary tangle protein antibody
      • Paired helical filament tau antibody
      • Paired helical filament-tau antibody
      • PHF tau antibody
      • PHF-tau antibody
      • PPND antibody
      • PPP1R103 antibody
      • Protein phosphatase 1, regulatory subunit 103 antibody
      • pTau antibody
      • RNPTAU antibody
      • TAU antibody
      • TAU_HUMAN antibody
      • Tauopathy and respiratory failure, included antibody
      see all

    Images

    • Immunohistochemistical detection of Tau antibody [E178] (ab32057) on formaldehyde fixed paraffin-embedded rat tongue sectionsAntigen retrieval step: Heat mediated. Buffer Used: Citric acid pH6. Permeabilization: None. Primary antibody incubated at 1/1000 for 2 hours @ 21°C in TBS/BSA/azide. Secondary antibody: anti Rabbit IgG Conjugated to Biotin (1/200). A strong pattern of immunostaining which appears to be mostly localised to nerve fibres and their cell bodies (Islet of Langerhans cells are also positive). In submitted image of central area of tongue coloured arrowheads indicate features: red for nerves cut in cross-section (T/S), each brown dot representing a single axon green for what appears to me to be small nerve fibres wrapping around a partial muscle fibre black for a Ganglion containing seven positive nerve cell bodies. Surrounding these are collagen fibres (C), adipocytes (A) and skeletal/striated muscle fibres in L/S ( M-

      See Abreview

    • Immunohistochemistical detection of Tau antibody [E178] (ab32057) on formaldehyde-fixed paraffin-embedded human salivary gland sections. Antigen retrieval step: Heat mediated.  Buffer Used: Citric acid pH6. Permeabilization: No.  Blocking step: 1% BSA for 10 mins @ 21°C. ab32057 incubated at 1/1000 for 2 hours @  21°C in TBS/BSA/azide. Secondary antibody:  anti rabbit IgG conjugated to Biotin (1/200). NB: An interesting pattern of positivity that seems to be supported by the Human Protein Atlas. Coloured arrowheads in the submitted image indicate features: red for positive serous glands, blue for positive intra-lobular collecting ducts, black for negative mucous glands (there is a serous demilune around this acinus), yellow for intralobular collecting ducts, green for nerve tracks in the interlobular areas, blue for positive interlobular collecting ducts. There appears to be a population of positive nuclei but this may b

    • Ab32057, at a dilution of 1/500, staining Tau in paraffin embedded human brain sections by Immunohistochemistry.
    • All lanes : Anti-Tau antibody [E178] (ab32057) at 1/1000 dilution

      Lane 1 : Untreated SH-SY5Y cell
      lysate
      Lane 2 : SH-SY5Y cell
      lysate SH SY5Y cell lysate treated with Oka/CalA. Cells are serum-starved overnight, and then treated with 1nM calyculin A and 500nM Okadaic acid for 2 hours at 37°C.

      Predicted band size: 79 kDa

    References

    This product has been referenced in:
    • Schmidt AF  et al. Intra-amniotic LPS causes acute neuroinflammation in preterm rhesus macaques. J Neuroinflammation 13:238 (2016). IHC-P ; Rhesus monkey . Read more (PubMed: 27596440) »
    • Wagner J  et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol 130:619-31 (2015). WB ; Mouse . Read more (PubMed: 26439832) »
    See all 15 Publications for this product

    Customer reviews and Q&As

    1-4 of 4 Abreviews or Q&A

    Answer

    Thank you for contacting Abcam regarding these antibodies.


    I am sorry that your customer is experiencing difficulties with these antibodies in WB. Based on the protocol information and information we have about the protein, there does not seem to be a good explanation for why you are detecting a band at the incorrect molecular weigt, and importantly, at the same molecular weight.


    I noticed that the customer has not performed a no primary control. Is the customer sure that the secondary antibody is working well and not the cause of background? I would advise performing this important control and considering testing another secondary antibody as well.

    If the secondary antibody does not appear to be the cause of the problem, I am happy to offer a replacement or credit.


    I look forward to your reply so that I may assist you further. Please do not hesitate to contact me if you have any additional questions.

    Read More
    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample
    Rat Tissue sections (Tongue)
    Specification
    Tongue
    Fixative
    Formaldehyde
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: Citric acid pH6
    Permeabilization
    No
    Blocking step
    (agent) for 10 minute(s) · Concentration: 1% · Temperature: 21°C

    Mr. Carl Hobbs

    Verified customer

    Submitted Nov 02 2010

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application
    Western blot
    Sample
    Human Cell lysate - whole cell (SH-SY5Y cell line)
    Loading amount
    12 µg
    Specification
    SH-SY5Y cell line
    Gel Running Conditions
    Reduced Denaturing (8)
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: RT°C

    Dr. Víctor Campa

    Verified customer

    Submitted Mar 09 2010

    Question
    Answer

    Thank you for taking the time to call me yesterday. Ab30663 recognises the isoform of Tau around the 48KDa mark. My colleague has spoken with a friend who works in this field. It is well known within the field that blotting against the non phospho form of Tau will give multiple bands (ranging from 45-65 KDa) this represents multiple isoforms of the target. The dominant isoform (even the phospho forms) will vary depending upon the species and the stage of development (which is why the other Ab to the same target detects a different sized band). There is a good review on the dephosphorylation of Tau written by Hanger et al about ten years ago that would be of use to you in this field. I think the Pub Med ID is: 11447841; however if you search Hanger DP a whole list of suitable papers can be found. I hope that this helps. Should you have any further questions then please do not hesitate to get back in touch with me.

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up